Ipsen and Skyhawk Therapeutics ink an exclusive collaboration
Ipsen and Skyhawk Therapeutics announced the signing of an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare neurological diseases. The agreement includes an option pursuant to which Ipsen would acquire exclusive license for the worldwide rights to develop successful development candidates (DC). Following successful DC nomination, Ipsen will […]
Kenai Therapeutics announces USD 82Mln series A financing
Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of allogeneic neuron replacement cell therapies for neurological disorders, today announced an $82 million Series A financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group, with participation from Euclidean Capital and Saisei Ventures. […]
ACROBiosystems Aneuro Partners with Diagnostic Biochips
ACROBiosystems, through ACRO Certify and under its Aneuro brand, recently announced the launch of in vivo electrophysiology solutions for neuroscience research with Diagnostic Biochips. Together, two companies are committed to a collaborative effort to accelerate neurological drug discovery and commercialization. Electrophysiology is a critical part of neuroscience research, especially when attempting to elucidate the neural network. Monitoring […]
Karuna Therapeutics onboards William P. Kane as CCO
Karuna Therapeutics, Inc. , a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, recently announces the appointment of Will Kane as chief commercial officer (CCO), effective February 6, 2023. “The addition of Will to our executive team represents an important step as we execute on […]
